NeuBase Therapeutics Inc NBSE:NASDAQ

RT Quote | USD
Last | 05/10/24 EDT
0.378UNCH (UNCH)
52 week range
0.36 - 4.80
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.378
  • 52 Week High4.80
  • 52 Week High Date05/22/23
  • 52 Week Low0.36
  • 52 Week Low Date05/06/24

Key Stats

  • Market Cap1.418M
  • Shares Out3.75M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta0.98
  • YTD % Change-48.93

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.378
  • 52 Week High4.80
  • 52 Week High Date05/22/23
  • 52 Week Low0.36
  • 52 Week Low Date05/06/24
  • Market Cap1.418M
  • Shares Out3.75M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta0.98
  • YTD % Change-48.93

RATIOS/PROFITABILITY

  • EPS (TTM)-7.78
  • P/E (TTM)-0.05
  • Fwd P/E (NTM)-0.21
  • EBITDA (TTM)-12.684M
  • ROE (TTM)-84.94%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NeuBase Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The...
Dov Goldstein M.D.
Independent Chairman of the Board
Todd Branning CPA
Interim Chief Executive Officer, Chief Financial Officer
Address
350 Technology Drive
Pittsburgh, PA
15219
United States

Top Peers

SYMBOLLASTCHG%CHG
ALLR
Allarity Therapeutics Inc
0.7852-0.0108-1.3568%
BBLG
Bone Biologics Corp
1.99+0.09+4.74%
EVLO
Evelo Biosciences Inc
0.0486+0.0086+21.4375%
PRFX
PainReform Ltd
0.801-0.019-2.3171%
SLRX
Salarius Pharmaceuticals Inc
0.4792-0.0108-2.2041%